North Rock Partners, LLC Bio Atla, Inc. Transaction History
North Rock Partners, LLC
- $4.99 Billion
- Q3 2025
A detailed history of North Rock Partners, LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, North Rock Partners, LLC holds 20,783 shares of BCAB stock, worth $18,496. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,783Holding current value
$18,496% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BCAB
# of Institutions
45Shares Held
13.7MCall Options Held
67.8KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.84MShares$4.3 Million1.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.73 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$1.22 Million0.04% of portfolio
-
Acadian Asset Management LLC Boston, MA930KShares$828,1110.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny801KShares$712,5610.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $32.3M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...